Lekpa Fernando Kemta, Chevalier Xavier
Faculty of Health Sciences, University of Buea, Buea.
Reheumatology Unit, Internal Medicine Department, General Hospital, Douala, Cameroon.
Open Access Rheumatol. 2018 Jan 9;10:1-11. doi: 10.2147/OARRR.S142892. eCollection 2018.
Relapsing polychondritis is a severe systemic immune-mediated disease characterized by an episodic and progressive inflammatory condition with progressive destruction of cartilaginous structures. This disease has for nearly a century kept secrets not yet explained. The real incidence and prevalence of this rare disease are unknown. The multiple clinical presentations and episodic nature of relapsing polychondritis cause a significant diagnosis delay. No guidelines for the management of patients with relapsing polychondritis have been validated to date. The challenges remain, both in the understanding of its pathophysiology and diagnosis, evaluation of its activity and prognosis, and its treatment. Possible solutions involve the sharing of data for relapsing polychondritis from worldwide reference centers. Thus, we would be able to evolve toward a better knowledge of its pathophysiology, the publication of new diagnosis criteria, which will include biological markers and imaging findings, the prediction of life-threatening or organ-threatening situations, and the publication of therapeutic evidence-based guidelines after performing at randomized controlled trials.
复发性多软骨炎是一种严重的全身性免疫介导疾病,其特征为发作性且进行性的炎症状态,伴有软骨结构的进行性破坏。近一个世纪以来,这种疾病一直存在尚未解开的谜团。这种罕见疾病的实际发病率和患病率尚不清楚。复发性多软骨炎的多种临床表现和发作性特点导致诊断显著延迟。迄今为止,尚未有针对复发性多软骨炎患者管理的指南得到验证。在理解其病理生理学和诊断、评估其活动度和预后以及治疗方面,挑战依然存在。可能的解决办法包括全球各参考中心分享复发性多软骨炎的数据。这样,我们将能够更好地了解其病理生理学,发布新的诊断标准,其中将包括生物标志物和影像学检查结果,预测危及生命或器官的情况,并在进行随机对照试验后发布基于治疗证据的指南。